共 34 条
[1]
[2]
[3]
Therapeutics targeting the IL-23 and IL-17 pathway in psoriasis[J] Ghoreschi Kamran;Balato Anna;Enerbäck Charlotta;Sabat Robert The Lancet 2021,
[4]
Long-Term Safety and Efficacy of Risankizumab in Patients with Moderate-to-Severe Chronic Plaque Psoriasis: Results from a Phase 2 Open-Label Extension Trial[J] Kim A. Papp;Saskia de Vente;Jiewei Zeng;Mary Flack;Byron Padilla;Stephen K. Tyring Dermatology and Therapy 2021,
[5]
A Real-World Evaluation of the Long-Term Safety and Efficacy of Infliximab in the Treatment Moderate-to-Severe Psoriasis.[J] Haque Emily K;Azhar Aaminah;Corbett John;Frieder Jillian;Wang Xuan;Menter Alan Dermatology and therapy 2020,
[6]
Emerging systemic drugs in the treatment of plaque psoriasis.[J] Balogh Esther A;Bashyam Arjun M;Ghamrawi Rima I;Feldman Steven R Expert opinion on emerging drugs 2020,
[7]
Management of psoriasis as a systemic disease: what is the evidence?[J] Korman N J The British journal of dermatology 2020,
[8]
Generalized pustular psoriasis in pregnancy; successfully treated with certolizumab pegol.[J] Mizutani Yoko;Mizutani Yuki H;Matsuyama Kanako;Kawamura Miho;Fujii Asami;Shu En;Ohnishi Hidenori;Seishima Mariko The Journal of dermatology 2020,
[9]
Mechanisms of microbial pathogenesis and the role of the skin microbiome in psoriasis: A review[J] Daniel J. Lewis;Warren H. Chan;Tiffany Hinojosa;Sylvia Hsu;Steven R. Feldman Clinics in Dermatology 2019,
[10]
Psoriasis: from Pathogenesis to Targeted Therapies.[J] Conrad Curdin;Gilliet Michel Clinical reviews in allergy & immunology 2018,

